mph Bangladesh

Molecule Info



Sitagliptin 50 mg as Sitagliptin PhosphateMonohydrate INN + Metformin HCl BP 500 mg and Sitagliptin 50 mg as Sitagliptin Phosphate Monohydrate INN and Metformin HCl BP 1000mg.

Suggested Use & Dosage

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Sitagliptin and Metformin is appropriate.

Dose of this combination should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg Sitagliptin and 2000 mg Metformin.

Sitagliptin/Metformin combination should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal side effects due to Metformin. The recommended starting dose in patients not currently treated with Metformin is 50 mg Sitagliptin/500 mg Metformin hydrochloride twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with Metformin.

The starting dose in patients already treated with Metformin should provide sitagliptin dosed as 50 mg twice daily and the dose of Metformin already being taken. For patients taking Metformin 850 mg twice daily, the recommended starting dose of this combination is 50 mg Sitagliptin/1000 mg Metformin hydrochloride twice daily.

Patients treated with an insulin secretagogue or insulin: co-administration of the combination with an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.


Do not use the combination of Sitagliptin & Metformin in patients with hepatic disease.

 Before initiating the combination and at least annually thereafter, assess renal function and verify as normal.

 May need to discontinue the combination and temporarily use insulin during periods of stress and decreased intake of fluids and food as may occur with fever, trauma, infection or surgery


Combination is contraindicated in patients with:

 Renal disease or renal dysfunction, e.g., as suggested by serum creatinine levels 1.5 mg/dL [males], 1.4 mg/dL [females]

 Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.

 History of a serious hypersensitivity reaction to the combination or sitagliptin, such as anaphylaxis or angioedema.

Adverse Drug Reaction(s)

The most common adverse reactions due to initiation of Metformin therapy are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.

Drug Interaction

Cationic drugs that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems.

Co-administration of Digoxin and Sitagliptin may slightly increase the mean peak drug concentration of Digoxin. But no dosage adjustment of digoxin or Sitagliptin is recommended.

Pregnancy Category (FDA) and use in Specific Population

PREGNANCY: Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women with the combination of Metformin/Sitagliptin or its individual components; therefore, the safety of the combination in pregnant women is not known. The combination of Sitagliptin & Metformin should be used during pregnancy only if clearly needed.

NURSING MOTHERS: It is not known whether Sitagliptin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this combination is administered to a nursing woman.


Because Sitagliptin and Metformin are substantially excreted by the kidney, and because aging can be associated with reduced renal function, combination of Sitagliptin and Metformin should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function.


Safety and effectiveness of Sitagliptin/Metformin in pediatric patients under 18 years of age have not been established


This product combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, and Metformin hydrochloride, a member of the biguanide class. Sitagliptin is a dipeptidyl peptidase-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, Sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.

The pharmacologic Pharmacology of Metformin is different from other classes of oral anti-hyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.

mph Class

Antidiabetic Agents.

Brand/Product Info

Total Products : 7       
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
GLIPITA M 50/1000 Beximco Pharmaceuticals Ltd Sitagliptin 50mg + Metformin Hydrochloride 1000mg Film Coated Tablet 10's: 270.00 MRP
GLIPITA M 50/500 Beximco Pharmaceuticals Ltd Sitagliptin 50mg + Metformin Hydrochloride 500mg Film Coated Tablet 10's: 250.00 MRP
SIGLIMET 50/1000 Square Pharmaceuticals Ltd. Sitagliptin 50mg+ Metformin 1000mg Tablet 4x5
SIGLIMET 50/500 Square Pharmaceuticals Ltd. Sitagliptin 50mg+ Metformin 500mg Tablet 2x10
SIGLIMET XR 100/1000 Square Pharmaceuticals Ltd. Sitagliptin 100mg + Metformin 1000mg XR Tablet 2x6
SIGLIMET XR 50/1000 Square Pharmaceuticals Ltd. Sitagliptin 50mg + Metformin 1000mg XR Tablet 3x6
SIGLIMET XR 50/500 Square Pharmaceuticals Ltd. Sitagliptin 50mg + Metformin 500mg XR Tablet 3x6
Simple Breath Test Might Diagnose Heart Failure An experimental breath test, designed to quickly identify patients suffering from heart failure simply by analyzing the contents of a...
Osteoporosis drug stops Breast cancer growth   News & Events News & Events     HIGHLIGHTS Osteoporosis drug stops growth of breast cancer...
Generic drug safety info loophole FDA plans to close generic drug safety info loophole The US Food and Drug Administration has announced plans to speed up the dissemination of...
Large trials unpublished   News & Events News & Events   HIGHLIGHTS Almost 1 in 3 of large clinical trials unpublished after...
TB activists boo Indian minister News & Events News & Events   HIGHLIGHTS TB activists at world conference boo Indian minister off...
Key bone marrow protein identified News & Events News & Events   HIGHLIGHTS Key bone marrow protein identified as potential new leukemia...